GlassScriptPhysician profile
Dolue D Ezeanolue
NPI 1700883014
$5,009.29
in general payments reported to CMS, 2019-2025
40 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $138 · 2021: $515 · 2022: $443 · 2023: $1,121 · 2024: $844 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Travel and Lodging: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.90 |
| Travel and Lodging | $269.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.76 | 2021-2025 | Relistor, Trulance |
| Stimwave Technologies Incorporated | $462.60 | 2019 | |
| Curonix LLC | $397.99 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $363.23 | 2019-2025 | |
| Novo Nordisk INC | $312.45 | 2021-2025 | Ozempic, Rybelsus |
| Forte Bio-Pharma LLC | $259.71 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Biohaven Pharmaceuticals, INC. | $216.06 | 2020-2021 | |
| Lilly USA, LLC | $158.13 | 2022-2025 | Mounjaro, Emgality, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $143.13 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $139.95 | 2024-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $132.08 | 2019-2024 | Breztri, Airsupra |
| Lundbeck LLC | $123.05 | 2023 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $116.43 | 2022 | |
| Boston Scientific Corporation | $103.04 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $93.03 | 2019-2020 | |
| Nalu Medical, INC. | $75.96 | 2022-2025 | Nalu Neurostimulation System |
| Allergan, INC. | $72.03 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $68.00 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $57.85 | 2023 | Givlaari |
| Amgen INC. | $44.60 | 2019-2025 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.63 | 2022-2024 | Caplyta |
| Collegium Pharmaceutical, INC. | $35.27 | 2020-2021 | |
| Kyowa Kirin, INC. | $33.71 | 2023 | Crysvita |
| Biodelivery Sciences International, INC. | $29.97 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $27.69 | 2022-2023 | Ztlido |
| Mdd US Operations, LLC | $26.78 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.47 | 2021 | |
| Avanos Medical | $21.98 | 2024 | Trivisc Sodium Hyaluronate |
| Inogen, INC. | $21.87 | 2022 | |
| Redhill Biopharma INC. | $21.73 | 2021 | |
| Spr Therapeutics, INC | $21.28 | 2024 | Sprint Pns System |
| Axsome Therapeutics, INC. | $19.62 | 2024 | Auvelity |
| Corcept Therapeutics | $19.38 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $18.66 | 2022 | |
| Averitas Pharma INC. | $18.40 | 2023 | Qutenza |
| Seqirus USA INC | $17.63 | 2025 | Flucelvax, Fluad |
| Biotronik Nro, INC. | $17.19 | 2024 | Prospera |
| Dexcom, INC. | $17.19 | 2025 | Dexcom G6 Transmitter |
| Grt US Holding, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolue Ezeanolue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.